Psilocybin Feasible for Treatment-Resistant Depression in NHS Setting
This NHS-based feasibility RCT provides one of the first placebo-controlled signals that a single 25-mg psilocybin dose with psychological support can produce large short-term reductions in depressive symptoms in treatment-resistant depression, while underscoring the unresolved problem of functional unblinding.
📅 Journal publication: Sep 2026(online Aug 6, 2026)·Last updated: Aug 11, 2026
Psilocybin shows promise for treatment-resistant major depression.
This study explores psilocybin as a potential treatment for patients with treatment-resistant major depressive disorder, which is a difficult-to-treat condition. The study found a significant improvement in depression scores with psilocybin compared to placebo, with a difference of -10.41 on the MADRS at week 3. These results suggest psilocybin could be beneficial for some patients with treatment-resistant depression, but a confirmatory trial is needed. The study was limited by its small size and feasibility-focused design. Psilocybin shows promise for treatment-resistant depression, warranting further investigation.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, Campbell-Coker K, Hambleton S, Seath P, Hignett R, Fennema D, Hampsey E, Tsapekos D, Thomas RJ, Cattell J, Jafari H, Day C, Borissova A, Lloyd M, Boardman-Pretty T, Seynaeve M, Askari F, Creed M, Baxter L, Rifkin-Zybutz R, Butler M, Jelen LA, Carter B, Young AH
Citation:Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature medicine. 2026;32(9):3430-3437. doi:10.1038/s41591-026-04541-0